Alkermes ALKS · NASDAQ
$41.22 +2.79% (+$1.12)
Summary
39 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 23% this fiscal year.
- Out of every 100 USD of revenue, 13 USD is left as free cash.
What to watch
- Repaying its net debt would take 4.9 years of operating profit.
- The share price is above the Bulios Fair Price.
- It earns only 2.1 USD a year on every 100 USD of invested capital.
- Out of every 100 USD of revenue, only 4.0 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 101.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.3% a year over 5 years. Over the last 3 years it grew by 9.9% a year. For the next fiscal year analysts expect revenue to grow by 23%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 15 USD
- Research and development 23 USD
- Sales and administration 54 USD
- Taxes and other 3.1 USD
- Net profit 4.0 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 4.0 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 16
- Hold 10
- Sell 3
Today's price within the analysts' price targets
The average target of $58.83 is 43% above today's price. 55% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Vivitrol 40%
- Aristada And Aristada Initio 31%
- Manufactured Product And Royalty 25%
- Manufacturing Revenue 3.9%
By region
- UNITED STATES 93%
- Foreign Country Excluding Specified Country 6.9%
- IRELAND 0.1%
Vivitrol brings in 40% of revenue.
Segments in detail